Xenon Pharmaceuticals Current Ratio 2012-2021 | XENE

Xenon Pharmaceuticals current ratio from 2012 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Xenon Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-09-30 $0.26B $0.01B 19.94
2021-06-30 $0.27B $0.02B 17.81
2021-03-31 $0.28B $0.01B 24.65
2020-12-31 $0.18B $0.02B 12.30
2020-09-30 $0.20B $0.02B 11.52
2020-06-30 $0.21B $0.02B 9.83
2020-03-31 $0.23B $0.05B 4.82
2019-12-31 $0.15B $0.04B 3.34
2019-09-30 $0.10B $0.01B 8.25
2019-06-30 $0.10B $0.01B 11.07
2019-03-31 $0.11B $0.01B 17.57
2018-12-31 $0.12B $0.00B 29.46
2018-09-30 $0.13B $0.00B 29.34
2018-06-30 $0.06B $0.00B 20.80
2018-03-31 $0.04B $0.00B 9.68
2017-12-31 $0.05B $0.00B 10.98
2017-09-30 $0.05B $0.00B 14.71
2017-06-30 $0.05B $0.00B 13.95
2017-03-31 $0.06B $0.00B 16.47
2016-12-31 $0.07B $0.00B 18.31
2016-09-30 $0.07B $0.00B 17.95
2016-06-30 $0.05B $0.00B 18.23
2016-03-31 $0.06B $0.00B 20.29
2015-12-31 $0.06B $0.00B 21.88
2015-09-30 $0.07B $0.01B 12.39
2015-06-30 $0.07B $0.01B 6.19
2015-03-31 $0.08B $0.02B 4.66
2014-12-31 $0.09B $0.01B 5.95
2014-09-30 $0.05B $0.02B 2.95
2014-06-30 $0.00B 0.00
2014-03-31 $0.00B 0.00
2013-12-31 $0.00B 0.00
2013-09-30 $0.00B 0.00
2012-12-31 $0.06B $0.02B 3.16
2011-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.649B $0.032B
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69